<DOC>
	<DOCNO>NCT02033369</DOCNO>
	<brief_summary>This study aim determine whether ventral striatal dopamine release mechanism reward motivation major depression , whether dopamine release low depression , whether DA release reward motivation predict response dopamine-targeted treatment pramipexole .</brief_summary>
	<brief_title>Imaging Dopamine Release Depression</brief_title>
	<detailed_description>Better understand basic neurobiology mood dysfunction appear necessary enable progress treatment depression . Reward motivation ( closely relate construct `` reward learning '' ) core neurobehavioral domain . ( 1,2 ) In major depressive disorder ( MDD ) , low reward motivation key aspect anhedonia , cardinal symptom MDD , related resistance treatment . ( 2,3 ) Although much learn reward motivation 's neurobiology relevance psychopathology , important gap knowledge impede application basic science finding improve treatment MDD . Reward motivation healthy subject involve ventrostriatal ( VST ) dopamine ( DA ) ( 4,5 ) , reduce reward motivation link MDD anhedonia . ( 3,6 ) These data suggest VST DA dysfunction might present MDD manifest clinically anhedonia . While DA neuroreceptor image study fail verify , methodologically compromise . Limitations include image method poor resolution functional striatal subregions , MDD sample heterogeneous antidepressant use , use self-report measure anhedonia , rather objective behavioral test specific domain reward motivation . This first study VST DA release ( PET image ) reward motivation , include patient MDD healthy volunteer . Reward motivation capture operationalized reward learn probabilistic reward task ( prior imaging ) . This clarify VST DA dysfunction link impaired motivation MDD . To test clinical implication MDD patient , assess relationship VST DA release , reward motivation , anhedonia outcome subsequent open label treatment DA D2 receptor agonist pramipexole .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Weight 44 kg 115 kg Meets DSMIV criterion principal diagnosis MDD , current major depressive episode , without psychotic feature Score &gt; 16 &lt; 29 17item Hamilton Rating Scale Depression Psychotropicna√Øve , define lifetime &lt; 2 week treatment antidepressant , anxiolytic antipsychotic Able tolerate treatmentfree period study participation Able provide inform consent A principal diagnosis current Axis I psychiatric disorder MDD Lifetime diagnosis psychotic disorder , bipolar disorder , mental retardation , attention deficit/hyperactivity disorder , substance use disorder ( include nicotine use disorder ) Serious suicidal risk history violent behavior would make participation protocol unsafe Any tobacco use prior three month ( already exclude abuse/dependence # 1 ) Illicit drug use prior three month , evidence history urine toxicology screen Women pregnant , nursing , postmenopausal , use hormonal method birth control Women use effective birth control method sexual abstinence ten day scan Any medical neurological problem might affect interpretation finding safety participation ( e.g. , blood dyscrasia , lymphoma , hypersplenism , endocrinopathies , renal failure chronic obstructive lung disease , malignancy , neurological disease brain , history seizure head trauma ) , low hemoglobin ( Hb &lt; 12 gm/dL male , Hb &lt; 10.5 gm/dL female ) ) Blood donation within 4 week study Metal implant paramagnetic object body might affect safety undergo MRI ( e.g. , heart pacemaker , shrapnel , bullet , surgical prosthesis surgical clip ) , determine consultation neuroradiologist accord guideline set forth reference : `` Guide MR procedures metallic object '' Shellock ; Lippincott Williams Wilkins , NY , 2001 More one major risk factor coronary artery disease ( e.g . hyperlipidemia , sedentary lifestyle ) . Smokers already exclude # 4 , diabetic # 8 Systolic blood pressure &gt; 140 diastolic blood pressure &gt; 90 base least two reading rest History untoward reaction amphetamine stimulant medication , pramipexole Any psychotropic treatment past 3 week ( depot medication past 6 month ) , except lorazepam , may administer needed prior image day Current , past anticipated exposure radiation workplace , participation nuclear medicine procedure , include research protocol ( In case previous exposure activity due research study , subject eligible condition list fulfil : 1 ) The inject dose dosimetry radiotracer know ; 2 ) Except research study , subject expose radiation ( workplace medical ) ; 3 ) Adding prior exposure exposure due study result yearly cumulative exposure lower FDA limit research study Family history schizophrenia parent , sibling , child Ongoing cognitivebehavioral interpersonal psychotherapy depression ( Supportive therapy exclusion ) Ongoing treatment cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>depression</keyword>
	<keyword>pramipexole</keyword>
</DOC>